Rotterdam, 7 July – Sensius, an Erasmus MC Spinoff company developing novel cancer treatment using hyperthermia, is receiving €300,000 from the UNIIQ investment fund and Erasmus MC. Using this investment, Sensius can make an important step forward to provide better treatment options for patients with head and neck cancer.
Watch the short introduction to thermal therapy for head and neck cancer and Sensius
500 000 New patients worldwide get diagnosed with head and neck cancer annually. Treatment is very challenging. International biological research has proven that thermal therapy attacks cancer cells. The HyperCollar3D, developed by Erasmus MC, steers the heat to the tumor while avoiding sensitive organs. This therapy should be available worldwide - Sensius will deliver.